Nandrolone vs Primobolan: What to Choose and for Whom

Nandrolone and primobolan (methenolone) are often contrasted as "mass" and "quality" anabolics. The editorial team proposes a different optic: to look at the clinical situations in which these substances were actually used, whom they were indicated for, and for whom their risks outweigh any expected benefit.

The clinical niche of nandrolone

Nandrolone decanoate is one of the few anabolic steroids that have retained registration as a medicinal product in a number of countries. Historically it was prescribed for anemia associated with chronic kidney disease, for some forms of osteoporosis, and also for cachexia in the context of severe chronic diseases.

The most convincing clinical data concern hemodialysis patients. In the randomized study by Johansen and colleagues (1999), nandrolone decanoate increased lean body mass and improved certain measures of physical function compared with placebo. Similar results were obtained in patients with HIV-associated wasting.

However, with the appearance of recombinant erythropoietin and other erythropoiesis stimulators, nandrolone's role in treating anemia declined significantly. Today it is considered only in isolated cases and in countries where it has remained available.

Importantly, even in these situations nandrolone is prescribed by a physician who weighs the benefits and risks for the particular patient and monitors hematocrit, lipids, liver function, and, in women, signs of virilization.

Why methenolone lost its clinical niche

Methenolone was used for approximately the same purposes — anemia due to bone marrow insufficiency and wasting — but its evidence base was always more modest. There are almost no modern randomized studies with it.

With the development of hematology (erythropoiesis stimulators, bone marrow transplantation, immunosuppressive therapy for aplastic anemia), the need for anabolic steroids in these conditions decreased. Methenolone gradually disappeared from the pharmaceutical markets of most countries.

Accordingly, the modern medical picture looks like this: nandrolone still has narrow indications in some jurisdictions, methenolone practically does not. This is the main difference from the standpoint of the "for whom" question.

For men with a testosterone deficiency, neither of the two substances is an agent of choice: in such a situation the guidelines recommend testosterone products themselves.

The myth of the "steroid for joints"

In the athletic environment there is a widespread belief that nandrolone "heals joints" and is therefore suitable for people with injuries or joint pain. This claim is worth considering separately, since it often becomes an argument in favor of the choice.

Nandrolone was indeed studied for its effect on collagen and bone tissue, and in some countries it was used for osteoporosis. Some animal studies point to an effect of anabolic steroids on collagen synthesis in tendons. However, there are no controlled studies showing that nandrolone heals injuries of the joints or ligaments in humans.

The subjective reduction in pain reported by users may have various explanations, in particular fluid retention and a general effect on well-being. At the same time, there are data that anabolic steroids alter the mechanical properties of tendons, and cases of tendon ruptures in users have been described.

Thus, a person with joint pain needs diagnosis by a traumatologist or rheumatologist and appropriate treatment, not a choice between nandrolone and methenolone.

Fertility and recovery of the hormonal axis

For men planning to have children, this question often becomes key. Any androgen suppresses the production of LH and FSH and, accordingly, spermatogenesis. Nandrolone stands out for especially pronounced suppression due to its additional progestogenic activity.

The review by Rahnema and colleagues (2014) describes anabolic steroid-induced hypogonadism as a common cause of severe testosterone reduction in young men. Recovery can last from several months to significantly longer periods, and in some people hormonal function does not fully recover.

The duration of recovery depends on the duration of use, the number of substances, the person's age, and the baseline state of the hormonal system. The long ester of nandrolone decanoate also prolongs the period during which the substance continues to act after the last administration.

Methenolone has no progestogenic activity, but it too suppresses the axis. Therefore, for a man planning to have children, non-medical use of either of these substances carries a direct risk to fertility.

Practical conclusion: if the question of fertility is relevant, the optimal step is a consultation with an andrologist and a semen analysis, not the search for a "less suppressive" steroid.

Women and athletes under doping control

For women, both substances carry a risk of virilization. Nandrolone was in the past prescribed to postmenopausal women for osteoporosis, and even under medical conditions deepening of the voice and hirsutism were observed. Methenolone, despite its reputation as a "female" steroid, is also a full-fledged androgen.

The signs of virilization to watch for are as follows:

• a change in the timbre of the voice, hoarseness;
• growth of facial and body hair in a male pattern;
• acne and increased oiliness of the skin;
• menstrual cycle disturbances;
• clitoral enlargement.

Changes to the voice and clitoris are often irreversible, even if use is stopped immediately after the first signs appear.

For athletes undergoing doping control, both substances are prohibited (section S1 of the WADA Prohibited List). Nandrolone has especially long metabolite detectability, so the risk of a positive result persists long after use is stopped.

Editorial conclusions

Nandrolone has a narrow but real clinical history — anemia in chronic kidney disease, wasting, osteoporosis — although today it has largely been displaced by other agents. Methenolone has practically disappeared from medical practice.

For healthy people, neither substance has indications. The myth of nandrolone "treating joints" is not supported by clinical studies, and its pronounced suppression of the hormonal axis makes it especially risky for men planning to have children.

Women and athletes under doping control must refrain from both substances.

We also recommend reading our materials on anabolic steroid-induced hypogonadism, on semen analysis and male fertility, and on evidence-based methods of recovery after tendon injuries.

References

1. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA. 1999;281(14):1275–1281.
2. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.
3. Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
4. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
5. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
6. World Anti-Doping Agency. The Prohibited List. International Standard. Montreal: WADA; 2025.